Charles R Ashby Selected Research

Cystic Fibrosis (Mucoviscidosis)

9/2021	Correction to: 2‑O, 3‑O desulfated heparin (ODSH) increases bacterial clearance and attenuates lung injury in cystic fibrosis by restoring HMGB1‑compromised macrophage function.
1/2021	2-O, 3-O desulfated heparin (ODSH) increases bacterial clearance and attenuates lung injury in cystic fibrosis by restoring HMGB1-compromised macrophage function.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles R Ashby Research Topics

Disease

48	Neoplasms (Cancer) 02/2024 - 11/2007
14	Hyperoxia 01/2023 - 01/2014
9	Inflammation (Inflammations) 10/2022 - 08/2013
8	Lung Injury 01/2023 - 01/2014
8	Premature Birth (Birth, Premature) 10/2022 - 01/2013
8	Infections 01/2022 - 11/2008
7	Colonic Neoplasms (Colon Cancer) 01/2023 - 01/2016
7	Cocaine-Related Disorders (Cocaine Addiction) 02/2010 - 11/2002
5	Ventilator-Associated Pneumonia 01/2023 - 06/2014
5	Acute Lung Injury 10/2020 - 01/2014
5	Schizophrenia (Dementia Praecox) 12/2018 - 06/2002
4	Breast Neoplasms (Breast Cancer) 11/2022 - 11/2007
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2022 - 01/2018
4	COVID-19 01/2022 - 10/2020
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021 - 07/2009
4	Bacterial Infections (Bacterial Infection) 01/2021 - 06/2014
4	Neoplasm Metastasis (Metastasis) 01/2020 - 08/2017
3	Prostatic Neoplasms (Prostate Cancer) 11/2022 - 05/2019
3	Pneumonia (Pneumonitis) 01/2022 - 01/2016
3	Colorectal Neoplasms (Colorectal Cancer) 07/2021 - 01/2018
3	Binge Drinking 07/2015 - 11/2012
3	Substance-Related Disorders (Drug Abuse) 01/2010 - 07/2005
2	Alcoholism (Alcohol Abuse) 05/2023 - 07/2015
2	Melanoma (Melanoma, Malignant) 02/2023 - 07/2019
2	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 01/2018
2	Cystic Fibrosis (Mucoviscidosis) 09/2021 - 01/2021
2	Carcinogenesis 01/2021 - 04/2011
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2021 - 01/2020
2	Ovarian Neoplasms (Ovarian Cancer) 07/2019 - 01/2017
2	Obesity 01/2017 - 06/2008
2	Hypothermia 02/2008 - 01/2007

Drug/Important Bio-Agent (IBA)

16	Adenosine Triphosphate (ATP)IBA 01/2024 - 11/2007
15	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2024 - 11/2007
12	Proteins (Proteins, Gene)FDA Link 01/2023 - 11/2007
10	HMGB1 Protein (HMG1)IBA 01/2023 - 01/2014
8	3-(2,4-dimethoxybenzylidene)anabaseineIBA 01/2023 - 06/2014
8	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2023 - 06/2014
8	Oxygen (Dioxygen)IBA 01/2023 - 06/2014
8	Dopamine (Intropin)FDA LinkGeneric 12/2018 - 01/2007
7	AntioxidantsIBA 01/2022 - 01/2014
7	CytokinesIBA 01/2022 - 08/2013
6	Member 2 Subfamily G ATP Binding Cassette TransporterIBA 01/2023 - 01/2016
5	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2023 - 11/2007
5	dimethylacetamideIBA 01/2023 - 08/2013
5	ErbB Receptors (EGF Receptor)IBA 08/2022 - 11/2007
5	Dopamine D3 ReceptorsIBA 01/2018 - 11/2002
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 03/2014
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023 - 01/2016
4	EnzymesIBA 10/2022 - 11/2018
4	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2021 - 11/2007
4	Antineoplastic Agents (Antineoplastics)IBA 09/2015 - 10/2009
4	Cocaine (Cocaine HCl)IBA 01/2010 - 11/2002
3	Phosphotransferases (Kinase)IBA 01/2023 - 09/2015
3	NF-kappa B (NF-kB)IBA 01/2023 - 09/2015
3	FlavonoidsIBA 01/2020 - 01/2017
3	LipopolysaccharidesIBA 11/2019 - 03/2015
3	EndotoxinsIBA 01/2019 - 08/2013
3	nilotinib FDA Link 01/2016 - 07/2009
3	N- (4- (2- (8- cyano- 1,3a,4,9b- tetrahydro(1)benzopyrano(3,4- c)pyrrol- 2(3H)- yl)ethyl)phenyl)acetamideIBA 11/2012 - 02/2008
3	Antipsychotic Agents (Antipsychotics)IBA 01/2007 - 06/2002
2	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2023
2	MicroRNAs (MicroRNA)IBA 01/2024 - 07/2019
2	CopperIBA 05/2023 - 10/2022
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2023 - 11/2007
2	4- (4- bromophenyl)- 3a,4,5,9b- tetrahydro- 3H- cyclopenta(c)quinoline- 8- sulfonamideIBA 01/2023 - 01/2021
2	Topotecan (Hycamtin)FDA LinkGeneric 01/2023 - 01/2016
2	tyrosine receptor (receptor, tyrosine)IBA 01/2023 - 02/2020
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2023 - 10/2010
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2023 - 02/2021
2	quinolineIBA 11/2022 - 01/2016
2	SolventsIBA 10/2022 - 08/2013
2	Excipients (Suspending Agents)IBA 10/2022 - 01/2022
2	ChemokinesIBA 01/2022 - 01/2022
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 10/2016
2	Nicotine FDA Link 12/2021 - 01/2020
2	Heparin (Liquaemin)FDA LinkGeneric 09/2021 - 01/2021
2	Actins (F Actin)IBA 01/2021 - 01/2020
2	Doxycycline (Periostat)FDA LinkGeneric 01/2021 - 11/2008
2	Nuclear Proteins (Protein, Nuclear)IBA 10/2020 - 06/2014
2	SofosbuvirIBA 01/2020 - 01/2017
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 01/2020
2	Ascorbic Acid (Vitamin C)FDA LinkGeneric 01/2020 - 10/2016
2	CurcuminIBA 07/2019 - 07/2019
2	PolyphenolsIBA 07/2019 - 08/2017
2	pyrimidineIBA 05/2019 - 09/2017
2	cariprazineIBA 12/2018 - 09/2018
2	Endothelin-1 (Endothelin 1)IBA 01/2018 - 01/2013
2	Silybin (Lagosa)IBA 01/2018 - 01/2017
2	elemeneIBA 09/2015 - 02/2014
2	Ethanol (Ethyl Alcohol)IBA 06/2015 - 11/2012
2	sphingosine kinaseIBA 03/2015 - 01/2013
2	bcr-abl Fusion ProteinsIBA 10/2010 - 07/2009
2	Imatinib Mesylate (Gleevec)FDA Link 10/2009 - 07/2009

Therapy/Procedure

22	Therapeutics 02/2024 - 11/2007
14	Drug Therapy (Chemotherapy) 01/2024 - 11/2002
6	Artificial Respiration (Mechanical Ventilation) 10/2020 - 01/2014
4	Self Administration (Administration, Self) 01/2010 - 07/2006
3	Chemoprevention 08/2017 - 01/2017
2	Immunotherapy 02/2023 - 11/2018
2	Mechanical Ventilators (Ventilator) 10/2020 - 06/2014